VistaGen Therapeutics, Inc.
VTGN
$0.61
-$0.02-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.67% | -28.63% | -10.71% | 3.22% | -8.70% |
| Total Depreciation and Amortization | 2.16% | 9.47% | 1.81% | 3.11% | 2.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.32% | 19.65% | -4.91% | -14.62% | 0.62% |
| Change in Net Operating Assets | -97.21% | 195.95% | -283.28% | -3.67% | 182.24% |
| Cash from Operations | -28.14% | 26.99% | -87.30% | 2.12% | 5.57% |
| Capital Expenditure | 56.67% | 7.69% | 26.14% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 482.35% | 95.30% | -217.56% | 245.73% | 94.54% |
| Cash from Investing | 210.64% | 88.07% | -249.53% | 224.88% | 94.58% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -1.46% | -204.44% | -- | -- | -- |
| Issuance of Common Stock | -91.44% | 4,905.02% | -71.40% | 66.61% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -92.36% | 1,758.47% | -23.73% | 66.61% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -211.69% | 176.06% | -139.27% | 20.43% | 48.96% |